Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 11Active not recruiting 6Terminated 1Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1

Interventions

pembrolizumab 9fludarabine phosphate 5fludarabine 5atezolizumab 4Paclitaxel 4Nivolumab 4Cyclophosphamide 4Cisplatin 4Cetuximab 4Carboplatin 4durvalumab 3Specimen Handling 3Pemetrexed 3Docetaxel 3Bevacizumab 3venetoclax 2ibrutinib 2encorafenib 2binimetinib 2Trastuzumab 2Standard of Care 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Practice Guidelines as Topic 2Platinum 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Leucovorin 2Ipilimumab 2Gemcitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × pertuzumab × 30 days × Clear all
NCT03199885 2026-05-29

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 3 Terminated
190 enrolled 13 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡